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Abstract
Background: Early treatment with tranexamic acid reduces deaths due to bleeding after post-partum haemorrhage.
We report the prevalence of haematological, coagulation and fibrinolytic abnormalities in Nigerian women with
postpartum haemorrhage.
Methods: We performed a secondary analysis of the WOMAN trial to assess laboratory data and rotational
thromboelastometry (ROTEM) parameters in 167 women with postpartum haemorrhage treated at University
College Hospital, Ibadan, Nigeria. We defined hyper-fibrinolysis as EXTEM maximum lysis (ML) > 15% on ROTEM.
We defined coagulopathy as EXTEM clot amplitude at 5 min (A5) < 40 mm or prothrombin ratio > 1.5.
Results: Among the study cohort, 53 (40%) women had severe anaemia (haemoglobin< 70 g/L) and 17 (13%)
women had severe thrombocytopenia (platelet count < 50 × 109/L). Thirty-five women (23%) had ROTEM
evidence of hyper-fibrinolysis. Based on prothrombin ratio criteria, 16 (12%) had coagulopathy. Based on EXTEM
A5 criteria, 49 (34%) had coagulopathy.
Conclusion: Our findings suggest that, based on a convenience sample of women from a large teaching hospital
in Nigeria, hyper-fibrinolysis may commonly occur in postpartum haemorrhage. Further mechanistic studies are
needed to examine hyper-fibrinolysis associated with postpartum haemorrhage. Findings from such studies may
optimize treatment approaches for postpartum haemorrhage.
Trial registration: The Woman trial was registered: NCT00872469; ISRCTN76912190 (Registration date: 22/03/2012).
Keywords: Fibrinolysis, Coagulation, Postpartum haemorrhage
Background
Tranexamic acid (TXA) administration reduces death
due to bleeding in trauma patients. Among patients
treated within 3 h of injury, TXA reduces death due to
bleeding by one third [1–3]. Early activation of fibrinoly-
sis is common after serious injury and contributes to the
coagulation abnormalities seen in bleeding trauma
patients [4, 5]. Hypo-perfusion and tissue injury are
thought to start the coagulopathy, although we do not
understand the molecular pathways [6].
Results from the WOMAN trial, a large randomised
trial conducted primarily in low and middle income coun-
tries, show that early tranexamic acid use reduces death
due to bleeding after postpartum haemorrhage (PPH) [7].
This suggests that fibrinolysis is also an important patho-
physiological mechanism in obstetric bleeding. However,
whereas increased fibrinolysis is common in trauma, its
association with PPH is less well known [8]. We re-
port the prevalence of hyper-fibrinolysis in women
with PPH in Nigeria.
Methods
The WOMAN trial was a randomised placebo con-
trolled trial of the effect of tranexamic acid on death,
hysterectomy and other surgical interventions in women
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with clinically diagnosed primary PPH [7]. Although the
diagnosis was clinical, we specified that diagnosis of
primary PPH could be based on an estimated blood loss
of more than 500 mL after vaginal birth or 1000 mL
after caesarean section, or any blood loss sufficient to
compromise haemodynamic stability. The diagnosis of
PPH could also be made using clinical judgement, inde-
pendent of the volume of blood loss. We have described
the methods in detail elsewhere [7]. We examined haem-
atological (full blood count) and haemostatic parameters
in a sample of 167 trial participants recruited at University
College Hospital, Ibadan, Nigeria. A total of 309 women
were recruited into the WOMAN trial at University
College Hospital. Because of occasional equipment failures
and lack of reagents the 167 (54%) women included in the
ETAC study were not a consecutive series. Although most
of the recruited women delivered at University College
Hospital, some patients were transferred from outlying
health facilities after they had developed PPH because they
required urgent medical support. In these women, blood
loss was estimated based on the history and observed
blood loss.
After completing consent procedures but before
giving the trial treatment (TXA or placebo), we drew
approximately 15 mL of venous blood and divided the
sample into three vacutainer tubes. We collected one
5 mL sample in a tube containing potassium EDTA for
full blood count analysis and two 4.5 mL samples in
tubes containing 0.5 mL sodium citrate (0.109 mol/L)
for coagulation and rotational thromboelastometry. We
used a five-parameter particle counter Sysmex KN ana-
lyser (Sysmex Corporation, Kobe, Japan) for the blood
count analysis. Anaemia was defined according to the
World Health Organisation definition of anaemia in
pregnancy as a haemoglobin below 110 g/L and below
70 g/L for severe anaemia [9].
After centrifuging the blood at 3000 g for 20 min, we
measured prothrombin time (PT), normalised prothrom-
bin ratio, activated partial thromboplastin time (aPTT),
Clauss fibrinogen and D-dimers using a HumaClot Junior
automated coagulation analyser. We measured ROTEM
thromboelastometry parameters at 37 °C using two of the
four channels (EXTEM, APTEM) of the ROTEM coagula-
tion analyser [TEM®, Munich, Germany]). In EXTEM,
coagulation is initiated using a small amount of tissue
factor and the development of the clot is expressed in
numbers and as a trace. In APTEM, coagulation is initi-
ated in the same way, but the addition of aprotinin or
tranexamic acid in the reagent inhibits fibrinolysis in vitro.
By comparing the two traces, the extent of fibrinolysis can
be assessed. If the sample is hyper-fibrinolytic, the same
degree of clot lysis seen in EXTEM is not present in
APTEM (Fig. 1). The following ROTEM variables were
examined from the EXTEM and APTEM traces (Fig. 2):
Clotting time (CT) which corresponds to the time re-
quired to trigger the process of coagulation, amplitude
of the clot at 5 min and 10 min (CA5 and CA10, re-
spectively), maximum clot firmness (MCF), clot lysis at
Fig. 1 ROTEM traces with (top) and without (bottom) hyper-fibrinolysis
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30 min and 60 min (LI30 and LI60, respectively), and
maximum lysis (ML). We stored the ROTEM reagents
at 2–8 °C with temperature monitoring and we used in
date reagents.
We conducted quality control (QC) analyses as per the
manufacturer’s recommendations. Before starting the
study, TEM staff trained the Nigerian study team to use
the ROTEM machine. We stored the ROTEM data on the
machine with a backup after each analysis. We collected,
cleaned and analysed the study data at the Clinical Trials
Unit of the London School of Hygiene & Tropical Medi-
cine. Fibrinolysis was assessed as the amount of clot lysis
on EXTEM (https://www.rotem.de/en/methodology/inter-
pretation/). We defined hyper-fibrinolysis as ML > 15% on
ROTEM EXTEM. This definition of hyper-fibrinolysis is
provided by the manufacturer and is widely used in
research studies [4]. Coagulopathy was defined as an
EXTEM A5 < 40 mm or a prothrombin ratio > 1.5. This
A5 definition of coagulopathy was based on studies of the
use of ROTEM to diagnose acute traumatic coagulopathy
in which a A5 < 40 mm predicted the receipt of massive
blood transfusion in 73% of patients [10, 11]. Normal
ROTEM values for peri-partum Nigerian women have not
been studied, so instead we have indicated the normal
values from a study of 161 healthy peri-partum Dutch
women [12].
Results
Table 1 shows the characteristics of the 167 women.
One hundred and twenty eight women (77%) gave birth
in the hospital, whereas 39 (23%) gave birth in other set-
tings and were admitted after PPH onset. Seventeen
(10%) women received colloids during fluid resuscitation
for PPH prior to sampling. The estimated mean blood
loss at the time of randomisation and blood sampling
was 1531 mL. One hundred and eight (65%) women lost
more than 1000 mL of blood.
Table 2 shows the full blood count and haemostatic
parameters. One hundred and sixteen (88%) women
were anaemic (haemoglobin < 110 g/L) and 53 (40%)
were severely anaemic (haemoglobin < 70 g/L) at the
time of sampling. Thirty eight women (33%) had a
microcytic picture (defined as an mean corpuscular vol-
ume < 80 fl), although there was no further investigation
to discover if this was due to iron deficiency or thalas-
semia traits or both. Twenty-six women (21%) were lym-
phopenic (lymphocyte count < 1 × 109/L). Forty-one (32%)
women had thrombocytopenia (platelet count < 100 ×
109/L) and 17 (13%) had severe thrombocytopenia
(platelet count< 50 × 109/L).
Thirty five women (23%) had an EXTEM ML> 15%. If
defined as an EXTEM A5 < 40 mm, coagulopathy was
present in 49 (34%) mothers. If defined as a prothrombin
ratio > 1.5, coagulopathy was present in 16 (12%) mothers.
Of the women with an EXTEM A5 < 40 mm, 72% had a
platelet count less than 100. The mean and median CT
were markedly different suggesting that there are outliers.
Of the 151 women with data for EXTEM CT, 127 women
had a CT ≤ 100, 22 women had a CT between 101 and
1000 and two women had CTs of 1814 and 3468. If the
two women with CT > 1000 are excluded, the mean (SD)
and median (IQR) clotting times were 93.6 (138.7) and 54
(45, 70) respectively. The median (IQR) for plasma
fibrinogen levels were 6.6 (3.2–12.3) g/L.
Figure 3 shows the relationship between estimated
blood loss and the coagulation parameters (maximal
lysis and A5). There was no significant correlation be-
tween estimated blood loss and maximal lysis (r = 0.01,
p = 0.86). There was a weak but statistically significant
negative correlation between estimated blood loss and A5
(r = − 0.35, p < 0.001). After excluding women transferred
Fig. 2 Annotated trace showing ROTEM parameters
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from outside health facilities, the results were essentially
the same (Maximal Lysis r = 0.06, p = 0.51; A5 r = − 0.46,
p < 0.001).
Discussion
Although 99% deaths from PPH occur in low and mid-
dle income countries, most of the research on the
haemostatic abnormalities in PPH is from high income
countries [13–15].
Among this cohort of women who received care at a
Nigerian hospital for PPH, nearly one quarter of women
had findings suggestive of hyper-fibrinolysis (ML > 15%).
This contrasts with studies in high-income settings
where hyper-fibrinolysis is considered less common in
PPH [14] de Lange et al. reported that 9% of women
after normal labour had ML of > 15% within 1 h of deliv-
ery of the placenta [12] with increased D-dimer levels.
Older studies looking at peri-partum changes in fibrin-
olysis show increases in tissue plasminogen activator
(t-PA) immediately after delivery, followed by increases
in plasminogen activator inhibitor (PAI-1) [16, 17].
In patients with trauma, ROTEM appears to under-
estimate the prevalence of fibrinolytic activation com-
pared with more sensitive measures such as plasmin-
antiplasmin complexes [4]. Further studies are needed to
examine which parameters are most sensitive in detect-
ing fibrinolysis in obstetric bleeding. Although we did
not find any correlation between estimated blood loss
and fibrinolytic activity, inaccuracy in blood loss esti-
mates could easily have obscured such an association.
Indeed, evidence from the WOMAN trial that adminis-
tration of tranexamic acid significantly reduces death
due to bleeding and re-operation for bleeding, strongly
suggests that fibrinolysis plays an important role in PPH.
Furthermore, a randomised trial conducted in France
has shown that there is an early increase in D-dimers
and plasmin-antiplasmin complexes in women with
active PPH and that this increase is attenuated among
women who received tranexamic acid [18].
Fibrinogen levels would be expected to fall with in-
creased fibrinolysis due to increased consumption and
fibrinogenolysis. However, despite the high prevalence of
hyper-fibrinolysis, the fibrinogen levels appeared to be
elevated. Compared to non-pregnant women, fibrinogen
levels are increased in pregnancy reaching their peak in
the third trimester [19]. Nevertheless, the fibrinogen
levels seen in our study are higher than in studies in
high income settings. This might be related to the effects
of inflammation due to acute and chronic infections
including HIV and their treatments [20]. The prevalence
of HIV in Nigeria is 3% and it is notable that 21% of our
sample were lymphopenic. Further studies in low and
middle income countries are need to confirm or refute
our results.
Many women were anaemic and the degree of anaemia
suggests that many were anaemic before developing PPH.
Anaemia in Africa has multiple aetiologies including iron
deficiency, functional iron deficiency (due infections such
as malaria and HIV); genetic conditions such as sickle cell
disease, thalassemia and glucose-6-phosphate dehydro-
genase deficiency; parasitic infections leading to blood loss
(e.g. hookworms); and drugs such as anti-retrovirals.
Furthermore, due to the expansion of the plasma volume
in pregnancy, haematocrit falls. Olatunbosun et al. found
that 54% of women booking into an obstetric clinic in
Uyo, Nigeria were anaemic, with most having evidence of
Table 1 Baseline characteristics of trial participants (N = 167)
Count (%) / Mean(SD)
Age (years)
Mean (SD) 31.9 (5.6)
Range 18–46
Time since delivery (hours)
≤ 3 103 (61.7%)
> 3 64 (38.3%)
Mean (SD) 4.2 (5.4)
Type of delivery
Vaginal 80 (47.9%)
Caesarean section 87 (52.1%)
Delivery in randomising hospital
Yes 128 (76.7%)
No 39 (23.4%)
Cause of haemorrhage
Uterine Atony 74 (44.3%)
Surgical trauma/tears 59 (35.3%)
Placenta praevia/accreta 21 (12.6%)
Other 12 (7.2%)
Unknown 1 (0.6%)
Systolic blood pressure (mm(Hg)
< 90 31 (18.6%)
≥90 135 (80.8%)
Missing 1 (0.6%)
Mean (SD) 110 (27)
Estimated volume of blood loss (mL)
≤ 1000 59 (35.3%)
> 1000 108 (64.7%)
Median (25th, 75th percentile) 1200 (1000, 2000)
Range 500–5530
Colloids given
Yes 17 (10.2%)
No 150 (89.8%)
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Table 2 Haematological parameters of trial participants at baseline (N = 167)
na Mean (SD) / Count (%) Median (25th, 75th
centile range)
Normal rangeb
Full Blood Count Variables
Red blood cell count (×10^12/L) 130 2.9 (1.0) 3.0 (2.3, 3.7) 3.8–5.8
Haemoglobin (g/L) 132 78.1 (35.6) 79.5 (56, 97) 110–165
Haemoglobin < 110 g/L 116 (87.9%)
Microcytic (MCV < 80) 38 (32.8%)
Normocytic (MCV 80–100) 75 (64.7%)
Macrocytic (MCV > 100) 3 (2.6%)
Haemoglobin < 70 g/L 53 (40.2%)
Hematocrit (%) 127 24.2 (7.7) 24.7 (19.2, 30) 35–50
Hematocrit < 33% 109 (85.8%)
Hematocrit < 25% 64 (50.4%)
White cell count (×10^9/L) 131 11.9 (8.1) 11.2 (5.3, 16.9) 3.5–10.0
White cell count > 25 (×10^9/L) 8 (6.1%)
Lymphocyte count (×10^9/L) 122 2.6 (2.4) 1.9 (1, 3) 1.2–3.2
Lymphocyte count < 1 (×10^9/L) 26 (21.3%)
Differential white cell count (monocytes)
(×10^9/L)
100 1.8 (1.8) 1.3 (0.6, 2.2) 0.3–0.8
Differential white cell count
(granulocytes) (×10^9/L)
100 8.7 (5.6) 7.7 (5.1, 11.5) 1.2–6.8
Platelet count (×10^9/L) 130 155.2 (101.7) 137 (86, 208) 150–390
Platelet count < 100 (×10^9/L) 41 (31.5%)
Platelet count < 50 (×10^9/L) 17 (13.1%)
Coagulation variables
Prothrombin time (PT, seconds) 137 19.0 (12.6) 15.2 (13.5, 18.8) 9.6–12.9
Normalised prothrombin ratio 133 1.2 (0.7) 1.0 (0.9, 1.2)
Normalised prothrombin ratio > 1.2 29 (21.8%)
Normalised prothrombin ratio > 1.5 16 (12.0%)
Activated partial thromboplastin time
(APTT, seconds)
133 35.9 (22.9) 30.4 (27.1, 35.6)
Thrombin time (TT, seconds) 124 13.1 (12.5) 10.4 (9.1, 12.6)
Normalised thrombin ratio 124 0.9 (0.9) 0.7 (0.6, 0.9)
Fibrinogen (g/L) 136 8.4 (6.6) 6.6 (3.2, 12.3)
Fibrinogen (< 1 g/L) 4 (2.9%)
Fibrinogen (< 2 g/L) 16 (11.8%)
Fibrinogen (< 4 g/L) 45 (33.1%)
D-Dimer (mg/L) 119 8.6 (8.2) 5.7 (2.3, 13.5)
Thromboelastometry (ROTEM® EXTEM)
variables
Clotting time (CT, seconds) 151 127.4 (336.9) 54 (45, 72) 34–66
Amplitude at 5 mins (A5, mm) 146 42.1 (15.8) 47 (35, 53)
A5 < 40 mm 49 (33.6%)
Amplitude at 10 mins (A10, mm) 149 51.6 (17.5) 58 (47, 63) 44–73
Maximum clot firmness (MCF, mm) 146 59.3 (17.5) 65 (56, 70) 55–78
Clot lysis at 30 min (LI30, %) 145 98.0 (10.8) 100 (100, 100)
Clot lysis at 60 min (LI60, %) 101 93.3 (10.1) 96 (92, 99)
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iron deficiency [21]. Women with antenatal anaemia may
have an increased risk of PPH and an increased risk of se-
vere anaemia after delivery [22, 23].
One third of women was thrombocytopenic and many
were severely thrombocytopenic. This also contrasts with
studies in high income countries in which thrombocytopenia
is relatively uncommon [24]. The low platelet counts (in the
context of the relatively well preserved coagulation factors)
may explain why so many women had an EXTEM A5 <
40 mm since EXTEM A5 values are influenced by platelet
and fibrinogen levels. Further studies are needed to assess
the FIBTEM and EXTEM A5 levels in similar populations
to differentiate the extent to which low platelet and/or fi-
brinogen levels impact on PPH progression. Several studies
have shown that a low A5 using ROTEM FIBTEM mea-
sured during the early phase of bleeding is associated with
an increased risk of severe PPH [25].
Our study has several weaknesses. Because we did not
collect blood samples prior to PPH onset, we cannot
determine whether the abnormal haematological values
(anaemia and thrombocytopenia) observed in this study are
a cause or consequence of the bleeding. Due to technical
problems with either blood samples or measurement in-
struments, the number of patients with available data was
less than the number enrolled. We did not compare our
results with a control group of women who did not experi-
ence PPH. Although the women in our study were a sam-
ple (54%) of all those recruited into the WOMAN trial at
University College Hospital, we do not believe they were
selected based on bleeding severity. The mean blood loss
among the 167 women who were included was similar to
that for the 142 women enrolled in the Woman trial but
not included in this ROTEM study [1530 ml (SD) 897 for
the included women versus 1548 (SD) 810] in women not
included in the ROTEM study]. Their systolic blood pres-
sures at baseline were also similar [110 mmHg (27) among
included women versus 103 (33) in women who were not
included]. It is possible that the reason for the high preva-
lence of coagulopathy found in our study is that our cohort
had more severe PPH than studies in high income settings.
Conclusions
Based on findings from a convenience sample of women
who delivered in a teaching hospital in Nigeria, hyper-
Table 2 Haematological parameters of trial participants at baseline (N = 167) (Continued)
na Mean (SD) / Count (%) Median (25th, 75th
centile range)
Normal rangeb
Maximum Lysis (ML, %) 150 14.7 (20.4) 9 (4, 15) 0–44
ML > 15% 35 (23.3%)
Thromboelastometry (ROTEM® APTEM) variables
Clotting time (CT, seconds) 152 245.2 (882.3) 58 (46, 81) 31–71
Amplitude at 5 mins (A5, mm) 143 44.0 (15.2) 48 (35, 54)
A5 < 40 mm 49 (33.6%)
Amplitude at 10 mins (A10, mm) 147 52.9 (16.8) 59 (46, 64) 43–72
Maximum clot firmness (MCF, mm) 144 61.4 (15.6) 67 (58, 71) 56–78
Maximum Lysis (ML, %) 147 5.9 (5.7) 5 (2, 8) 0–14
a Number of women with available data
b Reference ranges for full blood count variables were obtained from the Sysmex KN analyser output. Reference ranges for thromboelastometry variables were
obtained from literature [11]
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Fig. 3 Scatterplot of the relationship between estimated blood loss and ROTEM ML and A5
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fibrinolysis occurs in nearly 25% of women with PPH.
Further studies into the pathophysiological mechanisms
for hyper-fibrinolysis should help us to identify better
treatment strategies for women with PPH.
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